Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor ...

Nearly 99% of new chemicals used in food or food packaging since 2000 were green-lit for use not by the FDA but by the food and chemical industry, according to a 2022 analysis. During that period ...

Revenue for the fourth quarter was $57.6 million, with product revenues from Tavalisse, Rezlidhia, and Gavreto contributing significantly. Citi analysts have raised their price target for Rigel to ...

His previous roles include strategic advising for immuno-oncology biotechs and leading portfolio strategy at Juno Therapeutics, culminating in the FDA approval of Breyanzi® for lymphoma treatment.

This would increase transparency for consumers as well as the FDA's oversight of food ingredients considered to be safe, Kennedy said. Sign up here. "For far too long, ingredient manufacturers and ...

The triad of Tavalisse, Rezlidhia plus the more recently acquired Gavreto is emerging with a near $200M in collective sales for 2025, the analyst tells investors in a research note. Citi believes ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

REZLIDHIA more than doubled both bottles shipped ... dependent lower-risk MDS and orphan drug designation for MDS by the FDA. Furthermore, as part of Rigel-sponsored development programs and ...

Commercial strength continued in the fourth quarter for all products with record bottles shipped to patients and clinics and total bottles sold. The following table summarizes total bottles ...

Commercial strength continued in the fourth quarter for all products with record bottles shipped to patients and clinics and total bottles sold. The following table summarizes total bottles shipped ...